- CABOSUN results now subject of an oral presentation in
Presidential Symposium 3 on Monday, October 10 -
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Sep. 20, 2016--
Exelixis, Inc. (NASDAQ:EXEL) today provided an update on the timing of a
key data presentation for cabozantinib at the European Society for
Medical Oncology (ESMO) 2016 Congress, which is being held October 7-11,
2016 in Copenhagen, Denmark. Detailed results from CABOSUN, the
randomized phase 2 clinical trial of cabozantinib compared with
sunitinib in patients with previously untreated advanced renal cell
carcinoma (RCC), has been selected for the Presidential Symposium 3
session on Monday, October 10, 2016, starting at 16:30 CEST (local
Copenhagen time) / 10:30 a.m. EDT / 7:30 a.m. PDT.
The full logistical details for the CABOSUN data presentation are as
follows:
Oral Presentation
[LBA30_PR] “CABOzantinib versus SUNitinib (CABOSUN) as initial
targeted therapy for patients with metastatic renal cell carcinoma
(mRCC) of poor and intermediate risk groups: Results from ALLIANCE
A031203 Trial.”
Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology,
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Session: Presidential Symposium 3, Monday, October 10, 2016 –
16:30-18:10 CEST, Copenhagen room
Note: This is a National Cancer Institute Cancer Therapy Evaluation
Program (NCI-CTEP) study.
The late-breaking CABOSUN abstract was initially slated for an oral
presentation at a Proffered Paper session on Saturday, October 8, 2016.
Exelixis previously announced that data from the Exelixis-discovered
compounds cabozantinib and cobimetinib would be the subject of fifteen
presentations at the ESMO 2016 Congress. For full details on Exelixis’
presence at the conference, please see the company’s
press release issued on August 31, 2016.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and commercialization of new medicines
with the potential to improve care and outcomes for people with cancer.
Since its founding in 1994, three medicines discovered at Exelixis have
progressed through clinical development to receive regulatory approval.
Currently, Exelixis is focused on advancing cabozantinib, an inhibitor
of multiple tyrosine kinases including MET, AXL and VEGF receptors,
which has shown clinical anti-tumor activity in more than 20 forms of
cancer and is the subject of a broad clinical development program. Two
separate formulations of cabozantinib have received regulatory approval
to treat certain forms of kidney and thyroid cancer and are marketed for
those purposes as CABOMETYX™ tablets (U.S. and EU) and COMETRIQ®
capsules (U.S. and EU), respectively. Another Exelixis-discovered
compound, COTELLIC® (cobimetinib), a selective inhibitor of
MEK, has been approved in major territories including the United States
and European Union, and is being evaluated for further potential
indications by Roche and Genentech (a member of the Roche Group) under a
collaboration with Exelixis. For more information on Exelixis, please
visit www.exelixis.com
or follow @ExelixisInc on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920006880/en/
Source: Exelixis, Inc.
Exelixis, Inc.
Investors:
Susan Hubbard,
650-837-8194
Public Affairs and Investor Relations
shubbard@exelixis.com
or
Media:
Lindsay
Treadway, 650-837-7522
Public Affairs and Advocacy Relations
ltreadway@exelixis.com